Program
BL-M09D1
Its studies are mostly in Carcinoma, Transitional Cell · Carcinoma, Non-Small-Cell Lung · Digestive System Neoplasms, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 44 open or running | phase 2since Aug 12, 2026 | Apr 24, 2025 | May 2027phase 1 · NCT06954077 |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2025First study: phase 1 study in Digestive System NeoplasmsFirst studyNCT06954077 · 45 planned · China
- Jun 30, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07056556 · 31 planned · China
- Aug 12, 2026Phase 2 study in Gynecological MalignanciesPhase 2 reachedNCT07769229 · 126 planned · China
- Sep 18, 2026Phase 2 study in Carcinoma, Transitional CellNCT07837622 · 42 planned · China
Ahead
- May 2027Primary completion: phase 1 study in Digestive System NeoplasmsNCT06954077
- Dec 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07056556
- Dec 2028Primary completion: phase 2 study in Carcinoma, Transitional CellNCT07837622
- Dec 2028Primary completion: phase 2 study in Gynecological MalignanciesNCT07769229
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07837622Carcinoma, Transitional Cell · China | 2 | Not yet recruiting | Dec 2028 | 42 |
| NCT07769229Gynecological Malignancies · China | 2 | Not yet recruiting | Dec 2028 | 126 |
| NCT07056556Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Dec 2027 | 31 |
| NCT06954077Digestive System Neoplasms · China | 1 | Recruiting | May 2027 | 45 |
How it is read
Names in the registry
- “BL-M09D1”, 4 entries
Conditions, from the studies’ own filings
- Carcinoma, Transitional Cell, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Digestive System Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.